Marco Cassano

Dr. Marco Cassano

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FTFrancesco Saverio Tedesco
Francesco Saverio Tedesco
MGMattia Francesco Maria Gerli
Mattia Francesco Maria Gerli
LPLaura Perani
Laura Perani
SBSara Benedetti
Sara Benedetti
FUFederica Ungaro
Federica Ungaro
GCGiulio Cossu
Giulio Cossu
Genetically corrected mesoangioblasts from human iPSCs derived from limb-girdle muscular dystrophy patients produce muscle fibers expressing the therapeutic gene in a mouse model of the disease.

1 March 2016 in Developmental Cell
Verified
Journal Article
Closed access
GEGabriela Ecco
Gabriela Ecco
MCMarco Cassano
Marco Cassano
AKAnnamaria Kauzlaric
Annamaria Kauzlaric
JDJulien Duc
Julien Duc
ACAndrea Coluccio
Andrea Coluccio
DTDidier Trono
Didier Trono

1 February 2010 in Cell
Verified
Journal Article
Closed access
Messina GraziellaMessina Graziella
Messina Graziella
SBStefano Biressi
Stefano Biressi
SMStefania Monteverde
Stefania Monteverde
AMAlessandro Magli
Alessandro Magli
MCMarco Cassano
Marco Cassano
GCGiulio Cossu
Giulio Cossu

7 April 2015 in eLife
Verified
Journal Article
Open access
BRBenjamin Rauwel
Benjamin Rauwel
SJSuk Min Jang
Suk Min Jang
MCMarco Cassano
Marco Cassano
AKAdamandia Kapopoulou
Adamandia Kapopoulou
IBIsabelle Barde
Isabelle Barde
DTDidier Trono
Didier Trono
Human cytomegalovirus (HCMV) is a highly prevalent pathogen that induces life-long infections notably through the establishment of latency in hematopoietic stem cells (HSC). Bouts of reactivation are normally controlled by the immune system, but can be fatal in immuno-compromised individuals such as organ transplant recipients. Here, we reveal that HCMV latency in human CD34+ HSC reflects the recruitment on the viral genome of KAP1, a master co-repressor, together with HP1 and the SETDB1 histone methyltransferase, which results in transcriptional silencing. During lytic infection, KAP1 is still associated with the viral genome, but its heterochromatin-inducing activity is suppressed by mTOR-mediated phosphorylation. Correspondingly, HCMV can be forced out of latency by KAP1 knockdown or pharmacological induction of KAP1 phosphorylation, and this process can be potentiated by activating NFkB with TNF-α. These results suggest new approaches both to curtail CMV infection and to purge the virus from organ transplants.

8 June 2012 in Hepatology
Verified
Journal Article
Open access
PDF file
KBKarolina Bojkowska
Karolina Bojkowska
FAFabio Aloisio
Fabio Aloisio
MCMarco Cassano
Marco Cassano
AKAdamandia Kapopoulou
Adamandia Kapopoulou
FSFrancesca Santoni de Sio
Francesca Santoni de Sio
DTDidier Trono
Didier Trono
The liver is characterized by sexually dimorphic gene expression translating into sex-specific differences in lipid, drug, steroid hormone, and xenobiotic metabolism, with distinct responses of males and females to environmental challenges. Here, we investigated the role of the Krüppel-associated box (KRAB)-associated protein 1 (KAP1) epigenetic regulator in this process. Liver-specific KAP1 knockout (KO) led to strikingly sexually dimorphic phenotypic disturbances, including male-predominant steatosis and hepatic tumors with up-regulation of protein kinase B and extracellular signal-related kinases 1/2 mitogen-activated protein kinase signaling. This correlated with the sex-specific transcriptional dysregulation of a wide range of metabolic genes, notably those involved in retinol and sex hormone processing as well as in detoxification. Furthermore, chromatin immunoprecipitation followed by deep sequencing indicated that a number of dysregulated genes are direct targets of the KRAB/KAP1 repression system. Those genes include sexually dimorphic cytochrome P 450 Cyp 2d9 , glutathione S -transferase π, Cyp2a , Cyp2b , and Cyp3a gene clusters. Additionally, we identified a male-restricted KAP1-binding site in the fat-specific protein 27 gene, correlating with its male-predominant up-regulation upon Kap1 deletion, suggesting that the latter might be an important trigger in the development of male-specific hepatosteatosis and secondary tumorigenesis. Conclusion: This work reveals KRAB/KAP1-mediated transcriptional regulation as a central event in metabolic control hormones, drugs, and xenobiotics in the liver and further links disturbances in these processes with hepatic carcinogenesis. (Hepatology 2012)

1 March 2015 in Genes & Development
Verified
Journal Article
Open access
PDF file
KSKulwant Singh
Kulwant Singh
MCMarco Cassano
Marco Cassano
EPEvarist Planet
Evarist Planet
SSSoji Sebastian
Soji Sebastian
SJSuk Min Jang
Suk Min Jang
DTDidier Trono
Didier Trono
The transcriptional activator MyoD serves as a master controller of myogenesis. Often in partnership with Mef2 (myocyte enhancer factor 2), MyoD binds to the promoters of hundreds of muscle genes in proliferating myoblasts yet activates these targets only upon receiving cues that launch differentiation. What regulates this off/on switch of MyoD function has been incompletely understood, although it is known to reflect the action of chromatin modifiers. Here, we identify KAP1 (KRAB [Krüppel-like associated box]-associated protein 1)/TRIM28 (tripartite motif protein 28) as a key regulator of MyoD function. In myoblasts, KAP1 is present with MyoD and Mef2 at many muscle genes, where it acts as a scaffold to recruit not only coactivators such as p300 and LSD1 but also corepressors such as G9a and HDAC1 (histone deacetylase 1), with promoter silencing as the net outcome. Upon differentiation, MSK1-mediated phosphorylation of KAP1 releases the corepressors from the scaffold, unleashing transcriptional activation by MyoD/Mef2 and their positive cofactors. Thus, our results reveal KAP1 as a previously unappreciated interpreter of cell signaling, which modulates the ability of MyoD to drive myogenesis.